Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 Nov;38(5):599–605. doi: 10.1038/bjc.1978.255

Influence of micrococcus, BCG and related polysaccharides on the proliferation of the L1210 leukaemia.

R Verloes, G Atassi, P Dumont, L Kanarek
PMCID: PMC2009791  PMID: 728349

Abstract

A comparative study of the effects of BCG, Micrococcus lysodeikticus, and a series of structurally related polysaccharides (complement triggers) on the non-specific and specific immune resistance against L1210 lymphoid leukaemia was carried out and commented on. In contrast with authors of earlier reports, we were unable to generate any effective non-specific or specific immunotherapy after the graft of 10(4) leukaemic cells to 8--10-week-old CDF1 mice. However, when mice were prevaccinated with irradiated (8 krad X-rays) cultured cells combined with 1 mg of bacterium or polysaccharide one month before grafting 10(4) cells, they were given an immunoprotection that was more pronounced with the i.p. than with the i.v. route. Prevaccinated mice were afforded a stronger immunoprotection when boosted repeatedly with 1mg injections of bacterium or polysaccharide after tumour challenge.

Full text

PDF
599

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bianco C., Eden A., Cohn Z. A. The induction of macrophage spreading: role of coagulation factors and the complement system. J Exp Med. 1976 Dec 1;144(6):1531–1544. doi: 10.1084/jem.144.6.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Evans R., Alexander P. Mechanism of immunologically specific killing of tumour cells by macrophages. Nature. 1972 Mar 24;236(5343):168–170. doi: 10.1038/236168a0. [DOI] [PubMed] [Google Scholar]
  3. GLYNN J. P., HUMPHREYS S. R., TRIVERS G., BIANCO A. R., GOLDIN A. STUDIES ON IMMUNITY TO LEUKEMIA L1210 IN MICE. Cancer Res. 1963 Aug;23:1008–1015. [PubMed] [Google Scholar]
  4. Hunt J. S., Silverstein M. J., Sparks F. C., Haskell C. M., Pilch Y. H., Morton D. L. Granulomatous hepatitis: a complication of B.C.G. immunotherapy. Lancet. 1973 Oct 13;2(7833):820–821. doi: 10.1016/s0140-6736(73)90860-x. [DOI] [PubMed] [Google Scholar]
  5. Johnson R. K., Houchens D. P., Gaston M. R., Goldin A. Effects of levamisole (NSC-177023) and tetramisole (NSC-102063) in experimental tumor systems. Cancer Chemother Rep. 1975 Jul-Aug;59(4):697–705. [PubMed] [Google Scholar]
  6. Mansell P. W. Letter: Reactions to BCG. JAMA. 1973 Dec 24;226(13):1570–1571. doi: 10.1001/jama.1973.03230130058031. [DOI] [PubMed] [Google Scholar]
  7. Mathé G., Kamel M., Dezfulian M., Halle-Pannenko O., Bourut C. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy. Cancer Res. 1973 Sep;33(9):1987–1997. [PubMed] [Google Scholar]
  8. Mathé G., Pouillart P., Lapeyraque F. Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer. 1969 Dec;23(4):814–824. doi: 10.1038/bjc.1969.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Milas L., Scott M. T. Antitumor activity of Corynebacterium parvum. Adv Cancer Res. 1978;26:257–306. doi: 10.1016/s0065-230x(08)60090-1. [DOI] [PubMed] [Google Scholar]
  10. Miller T. E., Mackaness G. B., Lagrange P. H. Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells. J Natl Cancer Inst. 1973 Nov;51(5):1669–1676. doi: 10.1093/jnci/51.5.1669. [DOI] [PubMed] [Google Scholar]
  11. Mitchell M. S. Studies on the immunogical effects of BCG and its components: theoritical and therapeutic implications. Biomedicine. 1976;24(4):209–213. [PubMed] [Google Scholar]
  12. OLD L. J., CLARKE D. A., BENACERRAF B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959 Jul 25;184(Suppl 5):291–292. doi: 10.1038/184291a0. [DOI] [PubMed] [Google Scholar]
  13. Pinsky C. M., Hirshaut Y., Oettgen H. F. Treatment of malignant melanoma by intratumoral injection of BCG. Natl Cancer Inst Monogr. 1973 Dec;39:225–228. [PubMed] [Google Scholar]
  14. Prehn R. T. The immune reaction as a stimulator of tumor growth. Science. 1972 Apr 14;176(4031):170–171. doi: 10.1126/science.176.4031.170. [DOI] [PubMed] [Google Scholar]
  15. Sparks F. C., Silverstein M. J., Hunt J. S., Haskell C. M., Pilch Y. H., Morton D. L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973 Oct 18;289(16):827–830. doi: 10.1056/NEJM197310182891603. [DOI] [PubMed] [Google Scholar]
  16. Sultzer B. M. Infection with Bacillus Calmette-Guérin activates murine thymus-independent (B) lymphocytes. J Immunol. 1978 Jan;120(1):254–261. [PubMed] [Google Scholar]
  17. Verloes R., De Ridder M., Kanarek L. Biochemical properties that accompany the production of homogeneous antibody response: a general mechanism hypothesis [proceedings]. Biochem Soc Trans. 1977;5(4):1158–1159. doi: 10.1042/bst0051158. [DOI] [PubMed] [Google Scholar]
  18. Verloes R., Kanarek L., Atassi G. Antitumour immunoprotection by an immunobacterial lectin approach. Eur J Cancer. 1976 Nov;12(11):877–888. doi: 10.1016/0014-2964(76)90005-0. [DOI] [PubMed] [Google Scholar]
  19. Ward P. A. A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med. 1967 Aug 1;126(2):189–206. doi: 10.1084/jem.126.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wolfe S. A., Tracey D. E., Henney C. S. Introduction of "natural" killer' cells by BCG. Nature. 1976 Aug 12;262(5569):584–586. doi: 10.1038/262584a0. [DOI] [PubMed] [Google Scholar]
  21. Zatz M. M. Effects of BCG on lymphocyte trapping. J Immunol. 1976 Jun;116(6):1587–1591. [PubMed] [Google Scholar]
  22. Zbar B., Bernstein I. D., Rapp H. J. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst. 1971 Apr;46(4):831–839. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES